Exploratory Science Center

Last updated
Exploratory Science Center
Industry Pharmaceutical
Founded2016 (2016)
Headquarters320 Bent Street; Cambridge, Massachusetts
Parent Merck & Co.

The Exploratory Science Center (ESC) is a pharmaceutical company based in Cambridge, MA. [1] The disease agnostic research site was founded in 2016, and was led by Daria Hazuda (Chief Scientific Officer) until 2021. [2] [3] In late 2021 Juan Alvarez took on leadership as the interim head [4] and Marc Levesque took on leadership in 2022. [5] [6] The Exploratory Science Center is a subsidiary of Merck & Co.

Contents

The Exploratory Science Center consists of interdisciplinary scientific groups, including biologists, chemists, and data scientists. [7] [8] The site is co-located with a business development and licensing group [2] as well as the venture capital group Merck Ventures Fund. [9] The research focuses primarily on the microbiome and human immunity, although the research focus is intended to be fluid and flexible. [7] The site is kept intentionally small, so as to facilitate close collaborations and a startup-like atmosphere. [10]

History

The Exploratory Science Center site was originally occupied by a Schering-Plough innovation research site, which opened in 2006 and focused on small molecule drugs. [11] [12] The innovation research site became part of Merck & Co. when it merged with Schering-Plough in 2009. [13] Shortly after the merger, in 2010 Merck & Co. announced the closure of their Cambridge research site, after which it was occupied by Idenix Pharmaceuticals. [14] [15] [16]

Merck & Co. purchased the pharmaceutical company Idenix Pharmaceuticals in 2014 for $3.85 billion. [17] [18] The acquisition included its previously occupied research space in Kendall Square, a neighborhood within the Biotechnology industry in Boston. The 50,000 square foot space was converted to the current Exploratory Science Center space and began new operations in 2016 under the leadership of Daria Hazuda. [19] This transition back to research in Cambridge came as part of Merck's east coast reorganization, in which employees were transitioned out of New Jersey and Pennsylvania sites, and repositioned in Cambridge, as well as some in the San Francisco Bay Area. [20] [21] The Exploratory Science Center sits as a major component to the parent company Merck & Co. strategy of regional innovation hubs located in Cambridge, Massachusetts, San Francisco, and London. [22]

In 2022, Merck announced it would be expanding the Exploratory Science Center by hiring an additional 100 employees and adding 160,000 additional square feet to the Bent Street facility. [23] The site has capacity for 250 total scientists, and the expansion was paired with an extended remit for the site to include additional capability development as well as target identification and validation. [23]

Research

Mapping cell surface microenvironments

ESC scientists collaborated with researchers at Princeton University to develop visible-light-based techniques to map protein interactions on cell surfaces. [24] [25] In a collaboration between the ESC and Efficiency Aggregators (an energy efficiency company), an energy efficient biophotoreactor was developed to facilitate these light-powered biological studies. [26] This line of research was aimed at identifying drug targets using visible-light-based photocatalytic methods to interrogate cell surface protein microenvironments. [27] Applications included mapping proteins around PDL1, which is relevant to cancer immunotherapy. This is expected to continue as a line of research for the university laboratory, with applications to more cell surface proteins. [24]

Deep learning & natural products

The ESC research site has demonstrated an interest in natural product drug discovery using machine learning and genome mining approaches. This work included the development of an open source tool named DeepBGC, which provided a machine learning approach to biosynthetic gene cluster identification. [28] Researchers have tied this approach to the microbiome, as a way of understanding microbiome mechanisms and their interactions with the human immune system [29]

3D cancer tumor model technology

Researchers at the ESC published the development of a 3D tumor spheroid models which allow for the study of Anaerobic bacteria in the tumor microenvironment. [30] This technology has been used to understand the association of Fusobacterium nucleatum with Colorectal cancer.

Outreach & education

Scientists at the ESC partnered with the Bunker Hill Community College in 2018 to pair students with mentor researchers. [31] This was a semester-long program aimed at providing students with scientific exposure and development opportunities.

In 2019, the Exploratory Science Center hosted a microbiome conference titled the "Systems Biology of the Microbiome Symposium". [32]

Related Research Articles

The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare, Life Sciences and Electronics. Merck was founded in 1668 and is the world's oldest operating chemical and pharmaceutical company, as well as one of the largest pharmaceutical companies globally.

Schering-Plough Corporation was an American pharmaceutical company. It was originally the U.S. subsidiary of the German company Schering AG, which was founded in 1851 by Ernst Christian Friedrich Schering. As a result of nationalization, it became an independent company. In 1971, the Schering Corporation merged with Plough, Inc. to form Schering-Plough. On November 4, 2009 Merck & Co. merged with Schering-Plough with the new company taking the name of Merck & Co.

FUJIFILM Diosynth Biotechnologies, abbreviated FDB and also referred to simply as Diosynth, is a biopharmaceutical contract manufacturing organization that develops manufacturing processes and manufactures active ingredients and provides fill and finish services for pharmaceutical companies. FUJIFILM Diosynth Biotechnologies is the world's second largest contract manufacturer of biopharmaceuticals, with manufacturing facilities in Morrisville, North Carolina and College Station, Texas in the United States, Teesside, United Kingdom and Hillerød, Denmark in Europe, and recently added sites in Thousand Oaks, California and Watertown, Massachusetts. FUJIFILM Diosynth Biotechnologies operates a highly automated multipurpose manufacturing facility in College Station, Texas under the federal government's Center for Innovation in Advanced Development and Manufacturing (CIADM) program, which is the largest scale-out cell culture manufacturing facility in the United States.

<span class="mw-page-title-main">Human Genome Sciences</span> Former American pharmaceutical company, acquired by GlaxoSmithKline.

Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.

Takeda Oncology is a biopharmaceutical company based in Cambridge, Massachusetts. It is a fully owned subsidiary of Takeda Pharmaceutical.

<span class="mw-page-title-main">Carolyn Bertozzi</span> American chemist (born 1966)

Carolyn Ruth Bertozzi is an American chemist and Nobel laureate, known for her wide-ranging work spanning both chemistry and biology. She coined the term "bioorthogonal chemistry" for chemical reactions compatible with living systems. Her recent efforts include synthesis of chemical tools to study cell surface sugars called glycans and how they affect diseases such as cancer, inflammation, and viral infections like COVID-19. At Stanford University, she holds the Anne T. and Robert M. Bass Professorship in the School of Humanities and Sciences. Bertozzi is also an Investigator at the Howard Hughes Medical Institute (HHMI) and is the former director of the Molecular Foundry, a nanoscience research center at Lawrence Berkeley National Laboratory.

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but gets a third of its revenue from the United States. Organon & Co. is an example of increasing women's representation on Wall Street with over 50% of its board of directors and executive leadership being female.

<span class="mw-page-title-main">Sanford Burnham Prebys Medical Discovery Institute</span> Non-profit medical research institute

<span class="mw-page-title-main">Vicriviroc</span> Chemical compound

Vicriviroc, previously named SCH 417690 and SCH-D, is a pyrimidine CCR5 entry inhibitor of HIV-1. It was developed by the pharmaceutical company Schering-Plough. Merck decided to not pursue regulatory approval for use in treatment-experienced patients because the drug did not meet primary efficacy endpoints in late stage trials. Clinical trials continue in patients previously untreated for HIV.

CCR5 receptor antagonists are a class of small molecules that antagonize the CCR5 receptor. The C-C motif chemokine receptor CCR5 is involved in the process by which HIV, the virus that causes AIDS, enters cells. Hence antagonists of this receptor are entry inhibitors and have potential therapeutic applications in the treatment of HIV infections.

<span class="mw-page-title-main">Nicholas Lydon</span> British biochemist

Nicholas B. Lydon FRS is a British scientist and entrepreneur. In 2009, he was awarded the Lasker Clinical Award and in 2012 the Japan Prize for the development of Gleevec, also known as Imatinib, a selective BCR-ABL inhibitor for the treatment of chronic myeloid leukaemia (CML), which converted a fatal cancer into a manageable chronic condition.

Enumeral was a Cambridge, Massachusetts-based biotechnology company which developed monoclonal antibody immunotherapies through an 'immunoprofiling' platform that allowed it to scan the human immune microenvironment and identify and validate potential drug candidates. The company filed for Chapter 11 bankruptcy and arranged to sell its assets to Xoma Corporation in January 2018.

<span class="mw-page-title-main">Newhouse Research Site</span>

The Newhouse Research Site is a drug research facility situated 15 miles (24 km) east of Glasgow in central Scotland. It is located beside the M8 motorway in Newhouse, North Lanarkshire. The site is an early drug discovery research centre with a track record of generating a succession of products in the areas of anaesthesia and psychiatry. In 2007, the Royal Society of Chemistry Malcolm Campbell Memorial Prize was awarded to researchers for its work on a new anaesthesia drug, sugammadex. It currently employs 250 scientists across a range of disciplines including medicinal chemistry, molecular biology and drug metabolism. The site is currently the largest private drug discovery centre in Scotland, and one of the biggest in the UK.

<span class="mw-page-title-main">Merck & Co.</span> American multinational pharmaceutical company

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.

Laurie Hollis Glimcher is an American physician-scientist who was appointed president and CEO of Dana–Farber Cancer Institute in October 2016. She was elected a Member of the American Philosophical Society in 2019.

Tildrakizumab, sold under the brand names Ilumya and Ilumetri, is a monoclonal antibody designed for the treatment of immunologically mediated inflammatory disorders. It is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis in the United States and the European Union.

<span class="mw-page-title-main">Pembrolizumab</span> Pharmaceutical drug used in cancer treatment

Pembrolizumab, sold under the brand name Keytruda, is a humanized antibody used in cancer immunotherapy that treats melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, stomach cancer, cervical cancer, and certain types of breast cancer. It is given by slow injection into a vein.

Raymond F. Schinazi is an American organic medicinal chemist at Emory University with expertise in antiviral agents, pharmacology, and biotechnology. His research focuses on developing treatments for infections caused by human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV), herpes, dengue fever, zika, chikungunya, and other emerging viruses. These treatment options include antiviral agents as well as synthetic, biochemical, pharmacological and molecular genetic approaches, including molecular modeling and gene therapy.

Daria J Hazuda is a biochemist known for discovering the first HIV Integrase Strand Transfer Inhibitors (InSTIs) and leading the development of the first HIV integrase inhibitor to gain FDA approval, Isentress (raltegravir). Her lab also determined these inhibitors' mechanism of action and ways the virus could develop resistance to them. Hazuda has also performed extensive research and led the development of antivirals for Hepatitis C Virus (HCV) including Elbasvir and Grazoprevir. She currently serves as Vice President for Infectious Diseases Discovery for Merck and Chief Scientific Officer of their MRL Cambridge Exploratory Science Center.

Miram Merad is a French-Algerian professor in Cancer immunology and the Director of the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. She is the corecipient of the 2018 William B. Coley Award for Distinguished Research in Basic Immunology and a member of the United States National Academy of Sciences and the National Academy of Medicine.

References

  1. ↑ "MRL CAMBRIDGE ESC, LLC". Business Entity Summary
  2. 1 2 Keown, Alex. 2017. "Merck & Co. Opens Cambridge Exploratory Science Center". BioSpace.
  3. ↑ Leuty, Ron; Seiffert, Don. 2016. "Merck to open new Cambridge facility for microbiome research this year". Boston Business Journal.
  4. ↑ Juan Alvarez. LinkedIn. 2022.
  5. ↑ Marc Levesque. LinkedIn. 2022.
  6. ↑ Lecia Bushak. 2022. "Merck hires VP of immunology discovery". People Movers.
  7. 1 2 Mullard, Asher. 2019. "An Audience With Daria Hazuda: Hazuda spoke with Asher Mullard about the firm’s exploratory science agenda, its interest in the microbiome and its continued focus on antibiotics and HIV drugs". Nature Reviews Drug Discovery 18, 492-493.
  8. ↑ Nguyen, Tien. 2020. "A Conversation with Olugbeminiyi Niyi Fadeyi: Merck researcher finds new ways to merge chemistry and biology". ACS Cent Sci.
  9. ↑ MRL Ventures Fund: Investing in the Future
  10. ↑ Keown, Alex. 2017. "Merck Opens Exploratory Science Center". PharmaLive.
  11. ↑ 2006. "Schering-Plough Expanding Discovery Operations in Cambridge, MA". Technology Networks.
  12. ↑ 2006. "Schering-Plough expands presence in Cambridge". Boston Business Journal.
  13. ↑ 2009. "Merck, Schering-Plough set to complete merger". Reuters.
  14. ↑ 2010. "Merck to shut Cambridge research lab". Boston Herald.
  15. ↑ Sullivan, Thomas. 2010. "Massachusetts Code of Conduct: Merck Closing Cambridge Massachusetts Research Facility". Policy & Medicine.
  16. ↑ Weisman, Robert. 2010. "Merck will close lab in Kendall Sq.". The Boston Globe.
  17. ↑ Nickisch, Curt. 2014. "Cambridge Biotech Firm Idenix Bought By Drug Giant Merck For $3.85B". WBUR.
  18. ↑ Fidler, Bill. 2014. "Merck Scoops Up Idenix in $3.85B Buyout". Xconomy.
  19. ↑ Keown, Alex. 2016. "Merck & Co. Plans to Open Microbiome R&D Site in Former Idenix Facility in Cambridge". BioSpace.
  20. ↑ Terry, Mark. 2016. "Merck & Co. to Cut or Shift 360 East Coast Jobs, Add 100 in the Bay Area". BioSpace.
  21. ↑ Loftus, Peter. 2016. "Merck Cutting Drug Research Jobs at Three East-Coast Sites". The Wall Street Journal.
  22. ↑ "Merck Plans Radical Overhaul of R&D Unit". Drug Delivery and Development.
  23. 1 2 Rowan Walrath. 2022. "Merck to hire another 100 at newly expanded Cambridge research lab". Boston Business Journals.
  24. 1 2 Cross, Ryan. 2020. "Merck and Princeton scientists create method to map cell-surface microenvironments". Chemical And Engineering News.
  25. ↑ Geri, Jacob; et al. 2020. "Microenvironment mapping via Dexter energy transfer on immune cells". Science.
  26. ↑ Bissonnette, Noah; et al. 2020. "Design of a Multiuse Photoreactor To Enable Visible‐Light Photocatalytic Chemical Transformations and Labeling in Live Cells". ChemBioChem.
  27. ↑ Ryu, Keun Ah; et al. 2021. "Interrogating biological systems using visible-light-powered catalysis". Nature Reviews Chemistry.
  28. ↑ Hannigan, Geoffrey; Prihoda, David; et al. 2019. "A deep learning genome-mining strategy for biosynthetic gene cluster prediction". Nucleic Acids Research.
  29. ↑ Hannigan, Geoffrey; et al. 2020. "Understanding Human Microbiome Functionality & Immune Interactions Through Deep Learning". Pharmabiotics 2020.
  30. ↑ Kasper, Stephen. 2020. "Colorectal cancer-associated anaerobic bacteria proliferate in tumor spheroids and alter the microenvironment". Scientific Reports.
  31. ↑ 2019. "Mentorship Program with BHCC Students and Merck Enters Its Second Year".
  32. ↑ Systems Biology of the Microbiome Symposium
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.